Skip to main content
Satellos Bioscience Inc. logo

Satellos Bioscience Inc. — Investor Relations & Filings

Ticker · MSCL ISIN · CA80401L3083 TSX Professional, scientific and technical activities
Open in API
Filings indexed 216 across all filing types
Latest filing 2025-02-18 Regulatory Filings
Country CA Canada
Listing TSX MSCL

About Satellos Bioscience Inc.

https://satellos.com/

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing regenerative small molecule therapeutics for degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company's core mission is to restore the body's natural ability to regenerate muscle, addressing the failure of muscle repair inherent in these conditions. Satellos utilizes a novel approach rooted in muscle biology, focusing on restoring the asymmetric division of muscle stem cells (satellite cells), a process disrupted by the absence of dystrophin in DMD. Their strategy involves targeting the AAK1 protein to reactivate the natural repair mechanism. The lead therapeutic candidate, SAT-3247, is currently advancing into a Pediatric Phase 2 clinical study for DMD.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing an upcoming oral presentation at a scientific conference. It is not the actual presentation slides, financial report, or regulatory notice of a specific financial event (e.g., earnings release, dividend, management change). It does not fit specialized categories such as Investor Presentation (IP) because it is a scientific conference update rather than a detailed investor deck. It is therefore classified under the fallback category for general regulatory or miscellaneous announcements: RNS.
2025-02-18 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Business Wire press release announcing the completion of enrollment in a Phase 1 clinical trial for SAT-3247. It contains forward-looking statements and trial details but does not fit any specific financial filing category (e.g., earnings release, management discussion, share issuance, proxy materials, etc.). It is not a regulatory HTML/XBRL filing of financial data, but a general corporate announcement. Therefore, it defaults to the Regulatory Filings fallback category (RNS).
2025-02-10 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The filing is a Canadian NI 51-102F3 Material Change Report announcing the pricing and terms of an overnight marketed public offering of common shares and pre-funded warrants, including the gross proceeds, closing date, use of proceeds, and related party participation. This clearly constitutes a capital/financing update rather than an annual, interim, audit, management report, or other category. Therefore, it should be classified as a Capital/Financing Update.
2024-12-27 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of an equity offering, detailing the number of securities issued, gross proceeds, underwriters, use of proceeds, and related party transactions. This aligns with a capital/financing update rather than a full financial report or earnings release. Therefore, it is classified as a Capital/Financing Update (CAP).
2024-12-20 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release via Business Wire providing a clinical trial progress update (dosing of the first DMD participant in a Phase 1b study). It contains no financial results, no regulatory report attachments, no shareholder votes, and no changes in management or capital structure. It is not an earnings release, dividend notice, M&A announcement, or any other specific category. Therefore, by default it falls under ‘Regulatory Filings’ (RNS) as a general corporate announcement that does not fit other categories.
2024-12-11 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a Business Wire press release announcing that the company’s CEO will participate in an investor conference summit. It does not provide financial results, a report, regulatory voting information, or any formal filing; rather it is a general corporate announcement. This does not match any specific category, so it falls into the fallback category for miscellaneous regulatory announcements: RNS.
2024-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.